Hypofractionation for radiotherapy of prostate cancer using a low alfa/beta ratio possible reasons for concerns? An example of five dimensional radiotherapy

Acta Oncologica

Volumn 50, Issue SUPPL. 1, 2011, Pages 111-115

  Lennernäs, Bo ^a   Nilsson, Sten ^b   Levitt, Seymour ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RADIOTHERAPY; ORGANS AT RISK; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; SIMULATION; TREATMENT OUTCOME; TUMOR VOLUME;

BRACHYTHERAPY; DIAGNOSTIC IMAGING; DOSE FRACTIONATION; HUMANS; IMAGING, THREE-DIMENSIONAL; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 79957461209     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.562536     Document Type: Article

References (15)

1. Adami HO. The prostate cancer pseudo-epidemic. Acta Oncol 2010;49:298-304.
2. Budiharto T, Haustermans K, Kovacs G. External beam radiotherapy for prostate cancer. J Endourol 2010;24:781-9.
3. Ekl öv S, Essand M, Carlsson J, Nilsson S. Radiation sensitization by Estramustine. Studies on cultured human prostatic cancer cells. Prostate 1992;21:287-95.
4. DeWeese T, Dillehay LE, Shao Y, Williams JR. Low dose sensitization of human prostate cancer cells. IJROBP 1994; 30(Suppl):319.
5. Lennern äs B, Nilsson S. Calculated effects of displacement errors in external beam radiotherapy of prostatic adenocarcinoma. Acta Oncol 1999;38:203-8.
6. Fowler JF. Biological factors infl uencing optimum fractionation in radiation therapy. Acta Oncol 2001;40:712-7. (Pubitemid 33081979)
7. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. IJROBP 1999; 15: 1095-101. (Pubitemid 29144800)
8. Albertsen PC. WHO International Consultation on Prostate Cancer: A summary. Acta Oncol 2010.
9. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989;62:679-94. (Pubitemid 19194494)
10. Lennern äs B, Albertsson P, Edgren M, Nilsson S. Calculated and simulated effects of heterogeneous dose distributions in radiotherapy using the dose volume inhomogeneity corrected biological equivalent dose formula with special reference to prostate cancer. Oncol Rep 2007;18:1299-303.
11. Gao M, Mayr NA, Huang Z, Zhang H, Wang JZ. When tumour repopulation starts? The onset time of prostate cancer during radiation therapy. Acta Oncol 2010;49: 1269-75.
12. Thames HD, Kuban D, Levy LB, Horwitz EM, Kupelian P, Martinez A, et al. The role of overall treatment time in the outcome of radiotherapy of prostate cancer: An analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiother Oncol 2010;96:6-12.
13. Lennernas B, Levitt S, Nilsson S. Four and fi ve dimensional radiotherapy with reference to prostate cancer-defi nitions, state of the art and further directions. Acta Oncol (in press).
14. Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. IJROBP 2010;78:11-8.
15. Aihara M, Lebovitz RM, Wheeler TM, Kinner BM, Ohori M, Scardino PT. Prostate specifi c antigen and Gleason scale: An immunohistochemical study of prostate cancer. J Urology 1994;151:1558-64. (Pubitemid 24151302)